ArticleBMC infectious diseases2025
Factors associated with viral load non-suppression among adults with HIV in Sughd region, Tajikistan: a retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViral load suppression among people living with HIV is a key strategy for reducing HIV transmission. A global target for HIV elimination aims to have 95% of people living with HIV diagnosed, 95% of people diagnosed on antiretroviral therapy (ART), and 95% viral load suppression for those on ART. We aimed to assess viral load non-suppression rates and associated factors among people living with HIV on ART in the Sughd region of Tajikistan.
methodsWe conducted a retrospective cohort study of adults (≥ 18 years old) who were newly diagnosed with HIV in 2013–2022 and had received ART for ≥ 6 months in the Sughd Region. Data were collected from the national electronic HIV case surveillance system and cross-referenced with paper medical and laboratory records. We conducted multivariable Quasi-Poisson regression to identify factors associated with viral load non-suppression (defined as ≥ 1000 copies/mL on their latest viral load test).
resultsAmong the 1,871 people newly diagnosed with HIV who received ART for ≥ 6 months from 2013 to 2022, 11% were not virally suppressed. Over half (57%) were male, 38% were migrants, 73% were married, and the median age was 31 years (range 18–74). One-third (32%) had advanced HIV disease at diagnosis, 58% had been on ART for < 5 years, 94% were on a dolutegravir-containing regimen (DTG), and 9% died. Viral load non-suppression was 23% among people with stage IV at diagnosis and 43% among those not on DTG. Higher risk of viral load non-suppression was observed among male migrants and male nonmigrants compared to female nonmigrants (adjusted relative risk [aRR] and 95% confidence interval = 1.61 [1.13–2.31] and aRR = 1.48 [1.03–2.14], respectively), those who never-married vs. married (aRR = 1.56 [1.05–2.25]), those on ART for < 5 years vs. longer (aRR = 1.56 [1.05–2.29]), those initiating ART in 2013–2018 compared to 2019–2020 (aRR = 1.92 [1.28–2.88]), and those not on DTG (aRR = 3.86 [2.63–5.69]).
conclusionsViral load suppression among people living with HIV in the Sughd Region remains below the global 95% target. Viral load suppression may improve with increased treatment support for people with late diagnosis or those newly initiating ART, with a special focus on men and migrants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.